2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

PURPOSE: In the last decade, the research community has focused on defining reliable biomarkers for the early detection of Alzheimer’s disease (AD) pathology. In 2017, the Geneva AD Biomarker Roadmap Initiative adapted a framework for the systematic validation of oncological biomarkers to cerebrospi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Nucl Med Mol Imaging
Autori principali: Leuzy, A., Ashton, N. J., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., Blennow, K., Frisoni, G. B., Garibotto, V., Hansson, O.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2021
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8175301/
https://ncbi.nlm.nih.gov/pubmed/33674895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-021-05258-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi